Limitations Associated With Use of Allografts and Autografts to Bring Orthobiologics at Forefront

Orthobiology is a branch of science that develops bone and tissue replacement materials for fasthealing and quick recovery of injured muscles, broken bones, ligaments and tendons. Orthobiologics is considered as a highly lucrative market owing to significant growth opportunities. One of the major driver for the growth of this industry is certain limitations that are associated with autografts and allografts. Although, autografts are considered as gold standard for orthopedic procedures but the usage of autograft involves donor site morbidity and an additional surgery. While, the major concerns associated with allografts is risk of disease transmission along with the decline in theiravailability. Therefore, in order to overcome these drawbacks of the autografts and allografts, bone graft substitutes are being preferred for use in orthopaedic surgery.

According to the American Academy of Orthopedic Surgeons (AAOS), approximately 465,000 spinal surgeries were performed in the U.S in 2011. Of all the spinal fusion surgeries performed, 46% were for lumbar fusion, 42% were for cervical fusion and the remaining 13% were for thoracic or multi-level fusion procedures. This rise in number of spinal fusion surgeries has created the demand for bone graft substitutes and has consequently boosted the overall growth of this industry. In addition, rise in the incidence of arthritis, increase in geriatric population and increase in obesity rate has triggered the growth of this market. Technological advancements, growing demand for minimally invasive procedures and rising patient awareness are the other factors that has considerably augmented the growth of this market. The global orthobiologics market was valued at USD 3,754.6 million in 2012 and is expected to grow at a CAGR of 5.9%from 2013 to 2019 to reach at an estimated value of USD 5,519.9 million in 2019.

At present, viscosupplementation accounts for the largest share of the orthobiologics market. The growth in this market is attributed to growing popularity of knee treatments and its ability to act as an effective pain killer as compared to NSAIDS and others. This market is followed by bone morphogenetic proteins (BMPs) which is characterized by its ability to provide faster recovery, lesser pain and ability to stimulate patients own cells for regeneration. However, the market is expected to show a negative growth rateduring the forecast period due to decline in the sales of “INFUSE” a Medtronic product. Severe side effects associated with INFUSE due to its heavy off label usage led to recall of this product by the U.S FDA. Synthetic bone substitutes and stem cell based products are expected to witness a significant growth during the forecast period. The growth of these segments is witnessed due to reduced cost, quick recovery and eliminated risk of disease transmission.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1747

Geographically, North America and Europe dominates the orthobiologics market. The dominance in these region is witnessed due to rise in incidence of arthritis and higher obesity rates that has surged the demand for minimally invasive procedures such as bone grafting and growth factor treatment. These treatments offer enhanced well-being and durability, with minimal side effects while eliminating the need for repeated hospital visits. However, the Asia-Pacific region is expected to show highest growth rate during the forecast period. The demand for orthobiologics in this region is witnessed due to increase in number of orthopedic disease due to change in lifestyle, change in diet which all lead to increasing obesity rate and consequently leads to arthritis and other bone disorders. Moreover, rise in geriatric population and increase in sports related injuries are other factors likely to drive the growth of orthobiologics in this region.

The major players engaged in the orthobiologics market include Medtronic, Inc., DePuySynthes, Wright Medical Technology, Inc., Stryker Corporation, Orthofix, Inc., NuVasive, Inc., and other significant players.

Global Computational Biology Market to Exhibit 21.30% CAGR 2012-2018 as Companies Target Better Clinical Trial Outcomes

The global computational biology market is oligopolistic, led by major players who represented almost 80% of the market in 2011. Key players operating in the market include Simulation plus, Schrödinger, Certara, Compugen, Accelrys, and Entelos. Leading players are acquiring or merging with other companies to enhance their business and grow in the market, states a new report by Transparency Market Research (TMR). Case in point. Schrödinger acquired Synaptic Science and adopted the “Seurat” platform. This has helped Schrödinger to enhance its share in the market. Accelrys merged with Symyx technologies, allowing it to improve the company’s scientific data management, decision support, and analytics.

Although the global computational biology market is in its nascent stage, there exists high rivalry among existing players. The threat of new entrants is expected to be low as there is a need for capital-intensive infrastructure. Moreover, the lack of validation compels buyers to opt for branded software products, rather than the ones offered by new players.

Significant Funding By Governments Aids Advances in Computational Biology

Government initiatives across Europe, Asia Pacific, and America for the development of genomics and proteomics are expected to drive the global computational biology market. Investments by major IT players such as Infosys and TCS are expected to boost the growth of the computational biology market.

Significant funding by governments is accelerating the growth of the market. For instance, considerable funding has been done by Max-Planck Institute in collaboration with Federal Government of Germany. Similarly, The European Molecular Biology Laboratory’s European Institute (EMBL-EBI) with support by the U.K. government has funded a huge amount for research infrastructure.

There has been extensive research for the storage, retrieval, and integration of the data generated through virtual screening and sequencing. Innovations in the aforementioned areas will enable research on larger sets in much lesser time, and boost the computational biology market’s growth.

Market Players Need to Worry about Lack of Standardization in Computational Biology Tools

A huge amount of data is generated lacking any standardization, which is inhibiting the growth of the computational biology market. It is essential that tools be compatible with each other, enabling them to use the same data effectively. Moreover, the data storage in itself is acting as a major challenge for market players, states TMR. Statistical challenges resulting from the integrated analysis of high through-put biomedical research and genomic data need to be addressed. Mis-annotations owing to constant additions of new genomes into databases are also leading to problems, thus hampering the demand for computational biology tools and services. Shortage of skilled scientists who are well-trained in computers and biology sectors is also acting as a market challenge.

Cloud Computing to Offer Solutions to Data Storage Issues

The data storage issue is posing a huge challenge for the computational biology market. Cloud computing has solutions for this problem by offering scalability and flexibility to match the volume of data generated. Thus, cloud computing will open several opportunities of growth in the market.

View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1120

Problems such as the invasive nature of procedures for assessments and risks of futility in drug developments are being perceived as opportunities for the use of modeling and simulation.

By application, the drug discovery segment is expected to grow at a significant pace. North America is the leading segment in the computational biology market. However, countries such as China and India in Asia Pacific are expected to develop a massive opportunity for growth in the computational biology market. According to the report, the global computational biology market will be worth US$2.9 bn 2018.

This information is based on the findings of a report published by Transparency Market Research titled “Computational Biology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2012 - 2018.”

Hepatitis C Therapeutics Market Segment Forecast up to 2020

Hepatitis is defined as the inflammation of the liver due to an infection by a virus or other causative organism or toxin. Hepatitis C on the other hand, is primarily as a result of the infection by hepatitis C virus (HCV). With a cure rate between 50%-80%, and no commercially available vaccine as of yet, hepatitis C is considered a deadly disease with a moderate to high infection rate. It is the leading cause for liver transplantation in the U.K and North America.

The transmission of this virus in a majority occurs from injectables drug abuse, as the virus can only be transmitted via blood-to-blood contact. The secondary transmission factors include tattooing, sexual contact, healthcare (blood transfusion, organ transplant) mishaps, and other rare unknown cases. HIV infected individuals and AIDS patients too are at a higher risk of infection. The diagnosis of Hepatitis C is also very tricky as there lays a risk of misdiagnosis as the virus can go undetected in a liver biopsy sample. Liver enzyme levels may remain normal for an infected person for years, in some cases an infected person may go as long as 30 years without showing any symptoms of infection.

PCR amplification of purified and centrifuged biopsy samples done at specified time intervals are the best proven method for near accurate diagnosis.

This process is done so as to remove any errors caused as a result of false negatives by antibody immunoassay testing. However since PCR testing is quite expensive, initial screening is usually done via immunoassay method, in addition, immunoassay also determines the viral load and thereby help identify the stage of infection between acute and chronic. The acute stage of disease can generally be cured in majority of the cases, in some cases spontaneous curing has also been observed. Complete cure rate cannot be a possibility as Hepatitis C virus has various strains and is found to be mutative in nature. Chronic cases are seen in a majority of infected individuals and are also curable in some cases, but again among the majority, liver cirrhosis is observed, which may then require liver transplantation. Transplantation requires to be done with continuous medication, as chances of reinfection are very high. Therapy for Hepatitis C is not definitive but is generally done with a combination of medicines, namely pegylated-interferon-alpha and ribavirin, which is an antiviral. Other medications include boceprevir, ledipasvir, telaprevir, sofosbuvir and the novel simeprevir and sovaldi. These are either given as an addition to ribavirin or as a replacement, depending upon the condition, contraindication, genotype of virus and patient history.

At present the cost of the antiviral and interferon market remains the biggest hurdle for the proliferation of Hepatitis C therapeutics market. The prices vary from few hundred dollars to hundreds of thousands of dollars for a single dose. Insurances companies generally do not cover the complete cost of drugs in standard covers, often individuals who have very high premium are the only ones able to afford the treatment. The ongoing research into vaccination may also provide as a restraint in the future, as preventive vaccination has always shown greater success versus therapeutics.

Download Free exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2735

The market for Hepatitis C therapeutics remains in billions, with new combinations being patented every year, and each having their own market segment. They are at present one of the most sought after investment segment in the healthcare drugs industry. With entry of Asian players the prices too are bound to decrease, thereby potentially increasing therapeutics market. The North American market is the highest market by volume, followed by Europe, as in these regions reported cases are high in number, and so is the affordability of drugs.

The major cause for Hepatitis C transmission in developed nations is intravenous narcotic/psychedelic drug abuse, which is common in these regions. In developing markets of Asia and South America, the leading cause for transmission is healthcare exposure and their poor standards. This along with their population size make for a large market, however unavailability of affordable drugs is often the reason why markets haven’t been proliferated as of yet. However the recent growth of market in Asia Pacific is a positive sign for potential manufacturers. The rest of the world also follows a similar pattern.

Basal Cell Carcinoma Market - Trends, Opportunities and Forecasts up to 2024

Basal Cell Carcinoma Market: Overview

Basal cell carcinoma (BCC), which is also known as basal cell epithelioma is one of the most prevalent and common forms of skin cancers worldwide. BCC mainly arises from the basal cells, which are small cells that are round in shape and are located within the lower layer of the epidermis. These types of cancers can easily be identified, but if ignored it can cause several consequences with significant morbidity.

Basal cell carcinoma mostly affects head area including the scalp, face, neck, and hands. It’s characteristic features include waxy papules with central depression, pearly appearance, ulceration, bleeding if traumatized, crusted structures, and translucency, among others. For most of the cancer cases, these types of cancers have been observed that they do not metastasize or spread to other parts of the body.

However, they can invade the surrounding tissues by growing and hence causing damage to other neighboring tissues or organs of the body. Presently, basal cell carcinoma can be treated via different techniques, such as, radiotherapy, chemotherapy etc. that are being utilized for the treatment of several types of tumors or cancers. However, several manufacturers across geographies are studying different basal cell carcinomas and developing therapeutic drugs that are in different stages of their clinical trials, which will soon hit the global market.

Basal Cell Carcinoma Market: Key Growth Enablers

Major driving factors for the growth of this market include increasing prevalence of several skin cancers, global warming, rapidly depleting ozone layer, rising demand advanced therapeutics, and increasing awareness about several available treatment options. The increasing prevalence of several skin cancers, especially basal cell carcinoma, which accounts for most of the skin cancers worldwide, will continually provide growth towards this market.

According to the World Health Organization’s estimates in 2012, each year around 2 million to 3 million people suffer from these non-melanoma cancers worldwide. Global warming along with the depleting ozone layer will cause more incoming of harmful solar ultraviolet radiations into the earth’s atmosphere, which will further increase the number of skin cancer patients worldwide. According to the WHO estimates in 2012, around 300,000 patients will be added each year to the above estimates if the ozone layer is depleted by decreasing ozone levels by 10%. Also, increasing demand for advanced therapeutics, rising number of therapeutic drugs in several phases of clinical trials will continue to provide boost towards the growth of this market in future.

Basal Cell Carcinoma Market: Region-wise Insight

Geographically, North America and Europe are expected to dominate the basal cell carcinoma market in the near future. Major factors responsible for their dominance in this market include high prevalence of BCC in those regions, high demand for advanced therapeutics and high purchasing power of the population of those regions. However, emerging economies of Asia-Pacific, LATAM and the Middle East regions are also expected to show a rapid growth in this market. Major factors responsible for their rapid growth in near future would be the increasing awareness and demand for advanced therapeutics in these economies, rising medical tourism in these regions and increasing affordability of the people of these regions.

Get Free PDF Brochure for more Professional and Technical industry insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13223

Basal Cell Carcinoma Market: Key Players

Some of the major players operating or having their therapeutic drugs in clinical trials, include, 4SC AG, Berg Pharma, LLC, Bristol-Myers Squibb Company, Cannabis Science, Inc., Curis, Inc., F. Hoffmann-La Roche Ltd., Galderma S.A., Graceway Pharmaceuticals, LLC, MediGene AG, Meda AB, Novartis AG, Peplin, Inc., and Oncovir, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Stressful Modern Lifestyles Boost Global Sleeping Aids Market

Sleeping aids are medicines and medical devices that are solutions to an individual’s sleeping disorder. Seeping aids ensure the treatment and diagnosis for sleep disturbances and disorders. The symptoms of sleep disorders include daytime sleepiness, irregular breathing and abnormal sleeping behaviors and increasing movements during sleep. Sleep disorders has an adverse effect to human health. It can cause neural problems that may lead to accidents, lower the productivity of work done by the individual and can cause stress and depression. Moreover, sleep disorder can lead to major chronic diseases such as cardiovascular diseases, obesity and diabetes.

In today’s market, alternative and traditional sleeping aids are of great demand. Medical advice through prescriptions and over the counter medication has increased considerably. Therefore, the availability and accessibility of sleeping aids has grown over the past decade. In addition to sleeping pills, accessories such herbal supplements, sound machines and aromatherapy candles are also considered as major sleeping aids. Pillows and mattresses form the largest sleeping aid market but their growth rate is not as significant compared to sleep laboratories. Sleep laboratories carry out sleep testing of individuals suffering from sleep disorders. In such laboratories, sleep disturbances, movements during sleep and sleeping behaviors are ascertained through one or more sessions or therapy.

Sleeping aids market is witnessing significant growth and is expected to grow further in the coming years. With the rising aging population, stressful working conditions, inconsistent sleeping hours and change in lifestyle are all major reasons disturbing the sleeping habits in humans and thereby, driving the demands for sleeping aids. On the other hand, the major restraints inhibiting the growth of sleeping aids market globally are the side effects related to the use of sleeping pills and devices. Patent expiration of a number of sleeping drugs is the other reason that can result in the reduction in use of sleeping aids. The global sleep aids market is classified on the basis of four segments such as product, sleep disorder, medication and geography. The product segment has been segregated into sleep laboratories, mattresses and pillows, sleep apnea devices and medications.

North America dominates the global sleeping aids market, where U.S. is the largest market in terms of revenue. Stressful modern lifestyle and work life coupled with increasing demand for sleeping pills and rising awareness by numerous health organizations are all driving the growth of the North American sleeping aids market. North America sleep aids market is followed by Europe, Asia Pacific, Latin America and Middle East and Africa (MEA). Asia Pacific is the largest prospective region for the sleeping aids market. The growing demands for sleeping pills and medical devices from an enormous population of India and China is set to bolster the growth of sleeping aids market in the Asia Pacific region.

Get Free PDF Brochure for more Professional and Technical industry insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6544

Some of the key players in the sleeping aids market are Merck & Co., Sanofi, Pfizer, Koninklijke Philips N.V. (Philips), Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Care Fusion Corporation, SleepMed, Inc, Cadwell, Teva Pharmaceutical Industries Ltd, Natus Medical Incorporated, Compumedics Limited. and DeVilbiss Healthcare LLC.

U.S. Population Health Management Solutions Market - Latest Trends & Insights 2023

Transparency Market Research (TMR) has recently published a research study on the U.S. population health management solutions market, estimating this market to rise at a CAGR of 23.90% during the period from 2015 to 2023. The report also projects this market to reach US$45.7 bn by 2023 from a value of US$3.4 bn in 2014.The research report, titled “U.S. Population Health Management Solutions Market- Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023,” states that the implementation of the Affordable Care Act (ACA) in the U.S. has considerably driven the demand for population health management solutions in the country.

Apart from this, the rising geriatric population in the nation, together with the increasing incidence of chronic diseases, is also stimulating the demand for population health management solutions significantly in the U.S.

The need for heavy investment to develop the appropriate infrastructure is, however, restricting the growth of this market significantly. The implementation of these solutions also needs the deployment of skilled professionals, which sets an additional burden on end users. This factor is also limiting the demand for population health management solutions across the U.S., notes the research study.

The market study analyzes the U.S. population health management solutions on three fronts: source, mode of application, and end use. Software and service are the two main sources of population health management solutions in the U.S., says the report. Analysts expect the service segment to register the highest CAGR during the forecast period in this market.

By the mode of application, the research report segments the market into premise-based population health management solutions, cloud-based population health management solutions, and web-based population health management solutions. The cloud-based population health management solutions segment is projected to exhibit the fastest growth among all the segments based on the mode of application over the forecast period.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7412

Pharmaceuticals companies, healthcare providers, private insurance providers, government insurance providers, medical device organizations, research institutes, and diagnostic and imaging centers are the major end users of population health management solutions in the U.S., states the research study.

The market report also studies the competitive landscape of the U.S. population health management solutions market by profiling the major companies operating in this market. According to the study, Verisk Health Inc., Optum Inc., Wellcentrive, The Advisory Board Co., International Business Machine (IBM) Corp., Lumeris, Premier Inc., Cardigm, Health Catalyst, Healthagen LLC, F. Hoffmann-La Roche Ltd., ZeOmega Inc., NextGen Healthcare Information Systems LLC, Persivia, and Conifer Health Solutions LLC are the major participants in the population health management solutions market in the U.S.

Safety Syringes Market : Recent Industry Trends and Projected Industry Size by 2013 – 2019

The competitive landscape of the global safety syringes market is highly consolidated with the presence of a few key players, observes Transparency Market Research (TMR). These are Becton, Dickinson & Company, Smiths Medical, Retractable Technologies Inc., Revolutions Medical Corporation, Covidien plc, Terumo Corporation, and Unilife Corporation.

“Acquisitions and alliances are the focus of key players in the market to supplement internal growth with the objective to boost revenue growth”, says the lead author of the study. A case in point is, in December 2012, Becton, Dickinson & Company acquired Safety Syringes Inc. This led the former to strengthen its market position while also expanding its product portfolio.

An increasing number of investments in high-impact areas is another key growth strategy adopted by key players in the global safety syringes market. Companies are strategizing to invest heavily in sales and marketing at the global level. Top players in this market are also focused on research and development to develop newer safety syringes and needle devices with automated retraction.

Government Mandates for Safety Mechanism of Syringes Favor Market Growth

“The increasing number of needlestick injuries is the major factor driving the global safety syringes market”, says lead analyst of the study. According to the World Health Report 2002 analyzed by the World Health Organization, of the 35 million healthcare workers worldwide, almost 2 million undergo percutaneous exposure to infections every year. An increasing number of blood borne diseases such as hepatitis C, diphtheria, herpes, tuberculosis, hepatitis B, typhus, and malaria.

The continuous growth in the injectable drugs market is another major factor driving this market. This is because injectable drugs market is likely to display demand for drug delivery devices for drug administration that has been designed keeping up with safety requisites. Governmental legislations that require manufacturers to develop syringes equipped with safety mechanisms is also driving the global safety syringes market.

Price Factor Leads to Limited Use in Developing Nations

“The high cost associated with safety syringes is one of the major factors holding back the growth of the safety syringes market,” says the author of the study. According to the International Council of Nurses (ICN), a retractable safety syringe costs more than two times than a normal syringe. This factor is more prominent in developing nations such as China, India, and Brazil where healthcare providers tend to avoid spending money on safety syringes. Healthcare providers in these regions believe that needlestick injuries can be prevented by training healthcare workers to use normal syringes safely.

The growth of the safety syringes market is also impeded due to the rising popularity of non-invasive drug delivery techniques and continued development in alternate drug delivery technology that may be used in place of injectable drug delivery.

Get Free PDF Brochure for more Professional and Technical industry insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2079

The global safety syringes market will be valued at US$6.5 bn by 2019.

Non-retractable safety syringes account for the larger share of the market on the basis of product. In 2012, non-retractable safety syringes held the larger share of the market both in terms of volume and value.

North America is the largest market for safety syringes. In 2012, North America dominated the global market for safety syringes due to an early adoption of advanced equipment and advanced technology for rendering healthcare services.

The information presented in this review is based on the report, “Safety Syringes Market - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast, 2013 - 2019.”

E-Clinical Solution Software Market will reflect significant growth prospects during 2014-2020

E-clinical solution software comprises programs intended to make the process of data management in the global healthcare sector easier than can be done with conventional methods. The healthcare industry generates a massive volume of patient data every day, which requires careful storage in a way that also allows easy access for future use. The confidentiality of patient data also makes the storage system used for healthcare data crucial. This has driven the demand for digital data storage systems in the last few years and several major players have adopted various types of web-based e-clinical solution software to boost their productivity.

According to Transparency Market Research, the global market for e-clinical solution software was valued at US$3 bn in 2014. Exhibiting a robust growth rate of 13.80% from 2014 to 2020, the market is expected to rise to a valuation of US$6.8 bn.

How is cognitive learning impacting the global e-clinical solution software market?

One of the major points discussed at last month’s Digital Health Summer Summit in San Francisco was the potential applications of cognitive learning programs in the healthcare industry. While smart data logging and tracking software is becoming common in healthcare applications, the advent of cognitive learning in the field represents a crucial milestone for the industry.

Cognitive learning programs have the ability to not only organize and secure data, but also to come up with insights based on the data and to modify the conclusions when more data is added. This presents a major advancement for the healthcare industry owing to the increased accuracy and reliability cognitive learning solutions provide.

Which is the most popular delivery mode for e-clinical solution software?

By delivery mode, the demand for web-based e-clinical solution software dominates the global market. However, cloud-based delivery of e-clinical solution software is expected to become increasingly popular in the coming years. While web-based data storage revolutionized the healthcare industry by demonstrating the benefits of digitization, cloud-based data storage represents the logical next step of outsourcing data storage services. Cloud-based delivery of e-clinical solution software allows the end users to focus their resources on improving their core operations, which has driven the demand for cloud services.

Of the major end users of e-clinical solution software, the pharmaceutical industry took up the leading share in the global market in 2014. The consistent need for precise data in the pharmaceutical industry has made the sector a prominent end user of e-clinical solution software, with the increasing number of clinical trials expected to provide a major boost to the demand for e-clinical solution software in the coming years. However, clinical research organizations (CROs) are another major end user segment of the global e-clinical solution software market and are likely to exhibit the fastest growth in demand in the 2014-2020 forecast period.

Download Free exclusive Sample of this report:  http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2548

What does the increasing number of clinical trials in Asia Pacific signify for the e-clinical solution software market?

Currently, North America is the global leader in the e-clinical solution software market and holds a share of close to 60% due to the strong presence of the pharmaceutical industry in the region. Nevertheless, the increasing population in Asia Pacific is expected to result in an increase in the demand for e-clinical solution software, with North America’s share expected to drop to about 55% by 2020. Several pharmaceutical and life sciences companies are setting a firm foothold in rampant Asia Pacific economies, where the demand for pharmaceutical products is likely to grow significantly in the coming years.

Weight Loss Services Market set to Grow in Coming Years; Driven by Huge Consumer Base

Weight Loss Services Market: Overview

Overweight and obesity refer to excess body fat and it is related with increased weight-for-height. According to the World Health Organization (WHO) estimates more than 1.4 billion adults 20 years or older are overweight and obese. Obesity not only leads to loss of confidence among obese people, but is also a great concern from health standpoint. Overweight eventually leads a person to several diseases such as cardiovascular diseases (CVD), type 2 diabetes, strokes and even carry a risk of cancer. Obesity and weight gain has become one of the biggest concerns in the developed countries such as the U.S. owing to increasing adoption of sedentary lifestyle among the youth.

Weight Loss Services Market: Trends

The global weight loss services market is poised to grow in the coming years, thanks to increasing awareness among people about their health and well being. The huge consumer base is a key market driver for the growth of global weight loss services market and will continue to remain due to increasing global population, particularly in the Asia Pacific and Rest of the World.

Other prominent market drivers include consumer’s increased weight and rising disposable income among people in the developing countries. However, large number of tall and false claims misleads general public about the effectiveness of particular services. Such unfounded loss claims and misleading endorsements restrain the market growth for genuine products and services.

Weight Loss Services Market: Segmentation

The global weight loss services market can be segmented into four major segments, namely, weight loss food and diet chains, weight management programs, health clubs, and other approaches for weight reduction such as liposuction and bariatric surgery. The market is highly competitive in the developed world with simultaneous presence of several multinational and local players. The food and diet chain segment have been growing in incessantly even during the recession period and accounted for largest share in the global weight loss services market. NutriSystem, Inc. is one of the major players in this segment and is engaged in provided meal replacement and weight loss supplements.

Weight Loss Services Market: Region-wise Outlook

Geographically, the global weight loss services market can be segmented into four major geographical regions, namely, North America, Europe, Asia Pacific and Rest of the World. Historically, North America and Europe have been the largest play areas for the players in this market. The market for weigh loss services is getting a boost in the U.S. due to coverage provision of screening and counseling for obesity under the Affordable Care Act (ObamaCare).According to the Health & Social Care Information Centre, obesity levels in England have illustrated a sharp increase during the period 1993 to 2011.

Request free Sample pages of premium Research Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11897

The obesity and overweight population continues to grow in the OECD countries as well. A report – ‘Obesity and Economics of Prevention: Fit or Fat’ from OECD presents the scale of obesity epidemic and recommends that nations make policies to prevent the consequences of obesity on the health and economy of the nation. Therefore, the market for weight loss services is expected to grow continuously in the near future. However, as the economies in Asia Pacific are growing at a rapid pace, the changing lifestyle of people in this region is resulting in more people becoming obese. This presents lucrative opportunity for market players in this highly untapped regional market.

Weight Loss Services Market: Key Players

Some of the players in this market include Northcastle Partners, NutriSystem, Inc., Weight Watchers International, Inc., Jenny Craig, Inc., Medifast, Inc., BistroMD, Inc., and Rosemary Conley Diet & Fitness Clubs.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types and applications.

Gene Expression Reagents Market will Continue to Grow Strongly Through 2019

Gene expression is a process that results in the synthesis of a functional gene product with the help of the information coded on genes. These products usually are proteins with respect to coding genes but in case of non-coding genes such as tRNA (transfer RNA), or RNA (ribosomal RNA), the functional product is a functional RNA. The process of gene expression is significant in both prokaryotes (bacteria) and eukaryotes (multicellular organisms) in order to ensure the generation of macromoleular machinery for their life. Gene expression comprises transcription and translation processes. Transcription (DNA to RNA) refers to production of RNA copies of DNA with the help of the enzyme RNA polymerase. While translation (RNA to protein) is a process that results in the synthesis of proteins based on the information on the coding genes (messenger RNA). There is a possibility of the alteration of several steps in gene expression process such as in RNA splicing, post-translational modification of proteins and others. Gene regulation is the basis for morphogenesis, cellular differentiation and versatility and renders cell control over structure and function of the genes.

Gene expression profiling refers to the process of measuring the activity (expression) of several genes at once in to understand the cellular functions. This analysis can facilitate scientists to identify the molecular basis of phenotypic differences and also enables selection of gene expression targets for the future research studies. The various analysis techniques employed for gene expression are SAGE (serial analysis of gene expression), Real Time PCR-based gene expression profiling, microarray analysis, transcriptome sequencing and others. Gene expression reagents are the chemicals used in gene expression studies performed to determine the gene expression patterns. Sample preparation and isolation kits, sample labeling and amplification kits, TaqMan Gene Expression assay kits, gene expression hybridization kits and others are some of the examples of the commercially available gene expression reagents kits. Confirmation of appropriate gene expression is essential in order to ensure normal functioning of genes and any deviation from the normal expression pattern might result in the development of some disorder either genetic or acquired. Also, regulation of faulty gene expression inhibits the production of faulty functional products. For example, in case of cancer patients, RNA silencing is employed that includes the silencing of the cancerous gene expression.

The market for gene expression reagents can be analyzed on the basis of the reagents used in gene expression profiling along with application areas and geography. The reagents can be further segmented into the reagents used in PCR, Microarray, SAGE and others. The application areas that can be covered are drug discovery and research, biomarkers identification, clinical diagnostics and others. Geographically the market can be analyzed on the basis of four major regions namely North America, Asia-Pacific, Europe and RoW.

Download Free exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2379

The major factors favoring the growth of the market are consistent technological advances, increased intensity of research and development activities and development of gene expression databases across the globe. In addition, increased investments and funding by the government for genetic research along with elevated awareness levels further propel the market growth. On the other hand, high instrumentation costs along with lack of technical expertise in this field would impede the growth of the market. Owing to several advantages and increasing preference for personalized medicine, the scope for growth and uptake of gene expression studies will also increase and in turn increase uptake of gene expression reagents. Affymetrix, Inc., Illumina, Inc., Qiagen N.V., Thermo Fisher Scientific (Life Technologies Corporation), Bio-Rad Laboratories, Inc. and Agilent Technologies are some of the companies competing in gene expression reagents market.

Adoption of Healthcare Mobility Solutions to Consistently Rise Across the Globe

The rising use of mobile devices and integration of IT technologies in the healthcare industry has laid the foundation for global healthcare mobility solutions market. Healthcare mobility solutions refer to a wide range of software and hardware products that enable the transformation of conventional healthcare processes into automated and knowledge- and information-driven processes. Mobility solutions can make patient care more effective by reducing response time, enhancing workflow efficiency, reducing paper work and chances of erroneous manual recoding of essential health-related data, and reducing the overall healthcare costs and risks. From the point of view of healthcare providers, mobility solutions also help to increase patient throughput, make data organization and management easier as compared to manual records, and enable informed clinical decision-making through real-time access to patient information.

In the past few years, the global healthcare Industry has consistently increased the adoption of enterprise mobility. Much of the healthcare data earlier conveyed through papers have now been turned into electronic records, including test results, healthcare records, consultation notes, diagnoses, etc. This shift from manual data recording and management to electronically stored data and instant forms of data transfer has significantly increased the speed and efficiency of diagnosis and treatment, ultimately leveraging patient satisfaction. With the evolution of electronic communication, mobile devices such as smartphones, tablets, etc., are becoming the preferred tools for patients and healthcare providers as well for convenient communication, anywhere and anytime.

Increased Accessibility to Mobile Devices and the Internet Propels Market

A research undertaken by Alego Health, a U.S.-based healthcare IT services and solutions provider, over 72% nurses and 62% doctors in the U.S. were using smartphones and tablet computers in healthcare settings in 2012. The study also states that nearly 247 mn people in the U.S. in the same year downloaded mobile healthcare apps for personal use. By that year, over 40,000 healthcare mobile apps were available in the market, the number of which has consistently increased ever since.

The high rate of adoption of mobile devices in healthcare facilities, the unprecedented pace at which technological advancements are taking place in the field of mobile connectivity, and the improved network of high-speed Internet across the globe are the key factors propelling the healthcare mobility solutions market.

Healthcare Service Providers Account for Largest Share of Market

A report published by Transparency Market Research on the global market for healthcare mobility solution states that the market will expand at an exceptional 25.5% CAGR between 2015 and 2023. As a result, the market, which had a valuation of US$20.13 bn in 2014, is projected to rise to a valuation of US$148.66 bn by 2023.

View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4773

The healthcare mobility solutions market serves three major groups of individuals: patients, payers, and healthcare providers. For the patients, the market serves through mobile healthcare apps that allow patients to avail services such as electronic access to self healthcare records, lab results, apply for medical reimbursements, and others. For healthcare providers, healthcare mobility solutions help manage and organize healthcare data and streamline a number of processes in the healthcare a lot more efficiently than manual processes.

Payers, which comprises medical insurance companies or any third party taking care of the healthcare costs of a patient, can make fair use of the transparency provided by healthcare mobility solutions in terms of the actual costs incurred for a healthcare service availed by a patient (the client of the payer, in this case). Currently, it is the segment of healthcare service providers that accounts for the largest share of the global market, which is an estimated 45% in 2014, followed by the patients’ segment. On a global front, North America is the current leader of the market, followed by Europe and Asia Pacific.

Oncology Drugs Segment to Dominate Global High Potency Active Pharmaceutical Ingredients Market

Global high potency active pharmaceutical ingredient (HPAPI) market report provides comprehensive analysis considering various macro as well as micro economic factors. The report studies the HPAPI market from five perspectives: type of HPAPI, type of manufacturer, type of drug, therapeutic area, and geography.

The global high potency active pharmaceutical ingredient market report provides insights on contract versus captive HPAPI, synthetic versus biological HPAPI, and branded versus generic HPAPI. The global high potency active pharmaceutical ingredient market is also segmented into major therapeutic areas which include oncology, anti-diabetic, cardiovascular, central nervous system, musculoskeletal and others. From geography perspective, the market is studied for five main geographies: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America HPAPI market is sub-segmented for the U.S., Canada, while Europe HPAPI market is further segmented for Germany, U.K., and Rest of Europe. Asia Pacific HPAPI market is segmented for Japan, China and Rest of Asia Pacific. Latin America market is segmented for Brazil and Rest of Latin America. Middle East and Africa HPAPI market segmented for GCC Countries and Rest of Middle East and Africa.

Market size for each of the aforementioned segments and sub-segments is provided in US$ Mn considering 2013 and 2014 as base years and forecast from 2015 to 2023. The forecast model considers various factors such as drug patent expiry, therapeutic indication, prevalence, generic competition, anticipated drug approvals, impact of regulatory policies, industry pricing strategies and others. The research methodology is a blend of primary as well as secondary market research, where market estimates based on desk research are further refined considering inputs from expert interviews.

The global high potency active pharmaceutical ingredient market report also provides qualitative information on HPAPI manufacturing capabilities of major players in the market. The report also includes details on current regulatory policies. Major factors driving and restraining the global HPAPI market are also discussed in the report, while lucrative opportunities from future perspective are also mentioned. Furthermore, the global high potency active pharmaceutical ingredient market report also provides event impact analysis, which maps key events impacting market growth including facility expansion, mergers and acquisitions, changes in regulatory policies, drug approval, drug patent expiry and generic or biosimilars drug approval. Value chain analysis is also provided for comprehensive analysis. Porter’s five forces analysis and market share analysis of high potency active pharmaceutical ingredient market provides detailed information on current competitive landscape of the global HPAPI market. Furthermore, market attractiveness analysis provides information on most attractive geographies for HPAPI manufacturing.

View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=748

Finally, the report profiles major players in the global HPAPI market which include Alkermes plc, Cambrex Corporation, Dr. Reddy's Laboratories, Lonza Group, Novasep, Sandoz International GmbH, Pfizer, Inc., Sigma-Aldrich Co. LLC., WuXi AppTec. Each of the companies are profiled for parameters including: company overview, financial overview, product portfolio, business strategies and recent developments The report represents HPAPI market estimation and forecast in the form of 26 charts and figures, and 4 tables and comprises 85 slides.

Government Support Crucial for Widespread Adoption of Stem Cell Therapy

Stem cells are a type of human cells that give rise to the various types of cells found in the human body. Stem cells hold the potential to evolve into various types of human tissue, which has led to a growing acknowledgement of the obvious medical potential of this property. Stem cell therapy is becoming increasingly common in the treatment of various diseases and the increasing research in the field is expected to further drive the medical applications of stem cells in the coming years.

According to Transparency Market Research, government support is expected to be crucial in the global stem cells market’s expected rise from a 2013 valuation of US$26.3 bn to a valuation of US$119.5 bn by 2018. The market is expected to exhibit a robust 24.2% CAGR between 2012 and 2018.

Download Complete Healthcare Analytical Brochure:  http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

What are the major advances in the field of stem cells and their medical application?

In July 2016, a joint Dutch-Canadian research effort succeeded in discovering a viable method of increasing the amount of stem cells obtained from cord blood. Cord blood, which is blood from the placenta, contains a relatively small amount of stem cells per unit. The method formulated in the research allows researchers to increase the amount of stem cells obtained from cord blood, making this is a crucial advancement in the field of stem cell therapy.

The team discovered that mirR-125a, a microRNA, is responsible for the property of stem cells to self-renew. This genetic ‘switch’ remains activated in stem cells but is inactivated in the progenitor cells formed from the division of stem cells. Success in activating this switch would result in self-sustaining production of stem cells, which will be a major boost for the global stem cell therapy market.

In April this year, a research team at McMaster University in Hamilton, Ontario, discovered the protein responsible for the growth and development of blood stem cells. The Musashi-2 protein could be the key to helping thousands of patients of various blood disorders, as understanding the ambit of the protein could allow researchers to increase the number of viable stem cells available for therapeutic use.

What are some of the major drivers for the stem cells market?

The key driver for the global stem cells market is the increasing government support across the world. As widespread incorporation of stem cell therapy allows a nation to significantly improve the overall healthcare scenario, countries in North America and Western Europe have provided solid support to stem cell research. The acceptance of stem cell therapy in emerging regions is still lagging behind due to the lack of advanced medical infrastructure to adopt stem cell therapy, but the steady improvement of the healthcare sector in countries such as India and China is likely to be a major growth driver for the global stem cells market.

The increasing prevalence of neurodegenerative disorders is another major driver for the global demand for stem cells. Neural tissue can’t be regenerated or replaced as easily as structural tissues, and the ability of stem cells to develop into human cells provides the perfect avenue for treatment of neurodegenerative conditions.

Global Health Insurance Market to Rise as Disposable Incomes Improve for Most Income Groups

The concept of health insurance, in general, is objectively simple whereinan individual or organization purchase services or plans to avoid their risk in event of un-avoidable health conditions. Health insurance provides financial security to the people in their health care needs. The health insurance industry is one of the cardinal componentsof the global economy by virtue of the amount of revenue it collects, the extent of the global investment, and most prominently the indispensablesocio-economic role it plays by securing personal and business risk in the event of an unforeseen problems.

In 2014, the macro-economic condition across the globedemonstrated substantial improvement, with disposable income and GDP per capita rising in many countries and both the high income group and middle class increasing in number and financial resources. These aspectsaugur well for the globalhealth insurancecorporations such as United Health Group. Many payers (insurance companies) and investment firms are investing in digitalization of business process that strengthen their affiliations with customers across all geographies and product classifications. Many of the companies such as Cigna Corp. empower both consumers and its own resources to better shop for insurance, easier to understand and compare, and making products more transparent. Furthermore, insurance companies are exploiting on cloud computing, data analytics, and modeling techniques to improve their market penetration strategies, strengthen risk management and decrease claims fraud. Some of the companies are also investing in technology solutions to optimize business processes, regulatory compliance and increase alliance across the organizations. The key issues in healthcare insurance industry or rather more specific to insurance providers include rising competition, generally soft pricing conditions and tight profit margins. Moreover, the economic turbulence in 2008 has affected employer and corporate health insurance business in the developed countries to some extent due to cost cutting and lay-off of employees and slowdown of new recruitments. However, at individual levels,the market has not shown any significant slowdown.

Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5312

The U.S. has the largest health care system in the world and one of the biggest health insurances market. The U.S. health insurance market is consolidated by few major players which covers more than 80% of private and public (Medicare and Medicaid) managed insurance. The country’s largest health care provides include UnitedHealth Group Inc., Anthem Inc., Aetna Inc., Cigna Corp., and Humana Inc. The cardinal challenges for existing company or especially from new capital entrants in the U.S. health insurance market include immense competition and rising customer expectations. Success in this environment would be enhanced by expanding digital capabilities, empowerment of customers and distributors with self-service features and making insurance products easier to understand, compare and purchase. European health insurance market especially in EU5 countries (U.K., Germany, France, Italy, and Spain) is quite stable owing to significant contribution from government. The growth prospective for the private players is limited due to universal health coverage plans in these countries. Furthermore, the rest of Europe health insurance market for private players continue to challenge as economic recovery throughout the region is overshadowed by low business investment rates, and slower industry growth. In Asia Pacific, the growth prospects remain high due to increasing GDP, rise in disposable income, and growing trend toward health security. Furthermore, the growth of the middle class and high net worth population in Asia Pacific presents an immense opportunity for international players to exploit the emerging market.

Some of the key players in global health insurance market include UnitedHealth Group Inc.,Allianz SE, AIA Insurance Group, Express Scripts Holding Company, Zurich Insurance Group Ltd., AXA, Aviva plc, Aetna, Inc., International Medical Group, Apollo Munich Health Insurance, and Cigna Corporation.

Testosterone Replacement Therapy (TRT) Market to Face Lean Patch until 2024 as it Inches Close to Patent Cliff, says TMR

Patent Expiry Blow Dealt to TRT Market Could be Softened by Growing Prevalence of Hypogonadism

A wide range of testosterone replacement therapy (TRT) products containing different active ingredients have been made available by a large number of both global and local manufacturers. With various studies estimating the number of men affected by hypogonadism (testosterone deficiency) at 30% worldwide, the demand for TRT is poised to increase gradually in the years ahead. The condition primarily affects men aged between 40 and 79 years, making this demographic a key target segment for market players.

However, the market is currently at a crucial juncture with top performing products losing their patents in the next few years. This will no doubt cause a major dent in revenues of key market players. However, some of this impact could be reduced by the heightened demand for and awareness levels about the benefits of advanced TRT products. Many of these products are now being utilized in testosterone deficiency treatment are likely to support market growth during the forecast period.

TRT Creams and Gels Continue to See Strong Sales Worldwide but Injections Racing Ahead

For the purpose of this study, the global testosterone replacement therapy market has been segmented on the basis of product type into creams/gels, patches, injections, gums/buccal adhesives, implants and oral drug forms. Of these, the creams/gels segment led the global market, as overall sales were mainly impelled by key branded formulations such as AndroGel from AbbVie, Inc. Axiron from Eli Lilly and Company, and Fortesta, Testim, and Natesto from Endo Pharmaceuticals Inc.

Ease of use and comparatively less side effects have been the winning characteristics of gels/cream TRT products. However, this segment is expected to lose its current hold on the market owing to patent expirations of branded formulations.

TMR expects the injections product segment to witness the fastest CAGR from 2016 to 2024. This will be possible mainly because consumers are now more open to using these low priced products – a factor aided by the increasing availability of self-administered forms of these products globally.

On the basis of active ingredients, the TRT market is segmented into testosterone, methyl testosterone, testosterone undecanoate, and testosterone enanthate and testosterone cypionate. Of these, testosterone as an active ingredient dominated the global TRT market in 2015. However, other active ingredients are expected to cover much ground through the forecast period. The demand for ester forms of testosterone such as testosterone cypionate and testosterone undecanoate is projected to show a healthy rise. Testosterone undecanoate is expected to witness the fastest growth through the report’s forecasting horizon from 2016 to 2024.

North America Leads TRT Market but Scales Tipping in Favor of Asia Pacific

Of the five broad geographical segments of the global testosterone replacement therapy market, North America accounted for the largest share (84.7%) of the market and was followed by Europe In 2015. The other key segments are Europe, Asia Pacific, Middle East and Africa (MEA), and Latin America.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1097

The demand for advanced TRT products was especially strong in the U.S. in 2015 as the country accounted for 95% of the North America TRT market in that year, TMR has observed. Asia Pacific will greatly benefit from higher healthcare investments being channeled into the region and is expected to witness the fastest CAGR in the TRT market during the forecast period. China and India are markets that companies in the TRT market cannot ignore. In South Korea and Japan, on the other hand, the sizeable geriatric population and strong positive sentiments will aid the consumption of TRT products. Brazil is the key TRT market in Latin America with the single largest share 2015.

The key players operating in the global testosterone replacement therapy market are AbbVie, Inc., Allergan plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Mylan N.V., Novartis AG, and Pfizer, Inc. The testosterone replacement therapy market is somewhat consolidated with presence of a few large global players and some local vendors that are operating in the international market.

Patent Expiries of Blockbuster Drugs: an Unending Headache for the Global Pain Management Therapeutics Market

The pain management therapeutics market is likely to witness a decline worldwide in the next five years, as reported in Transparency Market Research’s recent publication, “Pain Management Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 – 2018”.

According to the report, the global pain management therapeutics market stood at US$40.93 billion in 2011. Declining at a -5.5% CAGR between 2012 and 2018, the market is expected to reach US$29.47 billion in 2018. The report analyzes the global market for pain management therapeutics based on three perspectives vis-à-vis geographic analysis, therapeutic classes of drugs, and pain management indications.

Chronic pain is one of the most common health concerns registered around the world. Due to the debilitating effect of chronic pain, the demand for pain management therapeutics has always remained significantly high. Several methods of pain management such as physiotherapy, chiropractor therapy, and minimally invasive procedures of pain management are easily available to patents.

Pharmaceuticals such as painkillers and analgesics, constitute the initial treatment prescribed by physicians. This encompasses drugs belonging to a combination of therapeutic classes such as anti-migraine agents, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, anticonvulsants, and others. The report indicates that while demand for pain management is growing, the impending patent expiry of blockbuster drugs will adversely impact the development of the pain management therapeutics market.

Patent expiration of blockbuster drugs such as Lyrica of Pfizer, Inc. and Cymbalta of Eli Lilly & Co. was a major setback for the market. The loss of market exclusivity of blockbuster drugs has drastically reduced the revenue generated in the pain management therapeutics market, thereby creating an opportunity for generic drug manufacturers to rise to the market’s forefront. While consumers would hope that leading manufacturers would invest in the production of novel drugs, insufficiency in novel drug discovery will further weaken the growth prospects of the pain management therapeutics market.

View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1059

The report has identified NSAIDs segment as the largest contributor to the revenue generated by the market in 2011. The key drivers propelling the NSAIDs segment are elaborated in the report. On the basis of indication, neuropathic pain and cancer pain dominated the pain management therapeutics market in 2011. The increasing incidence of cancer and diabetes has been cited in the report as the major reason behind the augmenting demand for pain management.

To measure the market’s performance in the global scenario, the report has segmented the global pain management therapeutics market into Asia Pacific, Europe, North America, and Rest of the World. The pain management therapeutics market in North America was valued at US$21,733.3 million in 2011 and is expected to decline to US$14,264.3 million by 2018. In terms of growth and market attractiveness, the report has identified Asia Pacific and the Rest of the World as the most lucrative markets for pain management therapeutics.

Separation Systems for Commercial Biotechnology Industry will lead the market to rise at a 6.8% CAGR from 2015 to 2023

Separation systems play a vital role in industrial biotechnology processes. These systems produce the desired products from small to large quantities and has wide area of applications. Liquid chromatography, membrane filters, flow cytometer instruments, centrifugation systems, and electrophoresis instruments are the major segments of the market. Each of the systems uses different method to carry out separations in the biotechnology, bio-pharmaceutical, agriculture, energy industries, etc.

The global Separation systems market for Commercial Biotechnology is anticipated to grow at a significant rate during the forecast period due to technological advancements, increasing awareness through conferences and exhibition, rising support and participation of government agencies, investment in R&D, and increase in number of biotechnology firms.

Chromatography systems have gained widespread popularity due to the introduction of novel technologies in chromatographic instruments and consumables. Flow cytometry has emerged as a leading, application-rich technology. Increasing demand and advancement of microarray technology boosts market growth. Laboratory automation has enabled scientists to process samples at low cost, and thus has played a major role in the experiments. Increasing number of conferences in the U.S., Europe, and Asia-Pacific is aiming to spread the new and upcoming innovations in the separation systems market. Growing awareness about chromatography has induced government organizations in the U.S., Europe, and Asia-Pacific to increase their investments, grants, and funds for the development of chromatography. Some of the market restrains includes high cost of systems and technologies, lack of innovation in electrophoresis equipment technology, and patent rights over MACS technique.

The global separation systems for commercial biotechnology market has been estimated based on product type, end-user, and geography. Based on product type, the global market has been segmented into liquid chromatography, membrane filters, electrophoresis instruments, flow-cytometer instruments, centrifugation systems, DNA microarray instruments, protein microarray instruments, MACS & FACS systems, and others. The liquid chromatography systems segment held the largest share of the market in 2014. The segment is likely to continue to dominate the market during the forecast period. Based on end-user, the separation systems market has been segmented into life sciences research and diagnostics, pharmaceuticals, food & cosmetics, energy, and agriculture.

Request free Sample pages of premium Research Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2104

The life sciences research and diagnostics end-user segment held the largest share of the market in 2014. The segment is anticipated to continue to dominate the market during the forecast period. It is also expected to record the fastest growth from 2015 to 2023. Rising number of genomic and proteomic researches in the life sciences research segment has increased demand for separation systems.

Geographically, the separation systems market has been categorized into four regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America held the largest share of the ultrasound devices market in 2014, followed by Europe. Asia Pacific was identified as the third largest market for ultrasound devices in 2014. The market in the region is expected to expand at a low CAGR during the forecast period. The reason for low market revenue and growth in North America is due to the high usage of other imaging technologies.

Danaher Corporation, Thermo Fisher Scientific, Inc., Waters Corporation, Becton, Dickinson and Company, GE Healthcare, and Merck KGaA are the major players operating in the global separation systems for commercial biotechnology market. Danaher Corporation is the leading player in the market.